Spero Therapeutics (SPRO) Competitors $1.18 -0.07 (-5.60%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends SPRO vs. AGLE, TTPH, ATYR, BMEA, LXEO, ADCT, TCRX, PYXS, LFCR, and ACRVShould you be buying Spero Therapeutics stock or one of its competitors? The main competitors of Spero Therapeutics include Aeglea BioTherapeutics (AGLE), Tetraphase Pharmaceuticals (TTPH), Atyr PHARMA (ATYR), Biomea Fusion (BMEA), Lexeo Therapeutics (LXEO), ADC Therapeutics (ADCT), TScan Therapeutics (TCRX), Pyxis Oncology (PYXS), Lifecore Biomedical (LFCR), and Acrivon Therapeutics (ACRV). These companies are all part of the "medical" sector. Spero Therapeutics vs. Aeglea BioTherapeutics Tetraphase Pharmaceuticals Atyr PHARMA Biomea Fusion Lexeo Therapeutics ADC Therapeutics TScan Therapeutics Pyxis Oncology Lifecore Biomedical Acrivon Therapeutics Aeglea BioTherapeutics (NASDAQ:AGLE) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, analyst recommendations, earnings and institutional ownership. Do analysts rate AGLE or SPRO? Spero Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 323.73%. Given Spero Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Spero Therapeutics is more favorable than Aeglea BioTherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aeglea BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Spero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, AGLE or SPRO? Spero Therapeutics has higher revenue and earnings than Aeglea BioTherapeutics. Aeglea BioTherapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAeglea BioTherapeutics$2.33M0.00-$83.82M-$75.59N/ASpero Therapeutics$103.78M0.61$22.81M$0.0716.86 Does the media refer more to AGLE or SPRO? In the previous week, Spero Therapeutics had 8 more articles in the media than Aeglea BioTherapeutics. MarketBeat recorded 8 mentions for Spero Therapeutics and 0 mentions for Aeglea BioTherapeutics. Spero Therapeutics' average media sentiment score of 0.23 beat Aeglea BioTherapeutics' score of 0.00 indicating that Spero Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Aeglea BioTherapeutics Neutral Spero Therapeutics Neutral Is AGLE or SPRO more profitable? Spero Therapeutics has a net margin of 3.30% compared to Aeglea BioTherapeutics' net margin of -22,195.36%. Spero Therapeutics' return on equity of 3.72% beat Aeglea BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aeglea BioTherapeutics-22,195.36% -132.05% -146.87% Spero Therapeutics 3.30%3.72%2.11% Which has more risk & volatility, AGLE or SPRO? Aeglea BioTherapeutics has a beta of 2.57, indicating that its stock price is 157% more volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Do insiders & institutionals have more ownership in AGLE or SPRO? 25.6% of Spero Therapeutics shares are owned by institutional investors. 6.6% of Aeglea BioTherapeutics shares are owned by insiders. Comparatively, 4.5% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer AGLE or SPRO? Aeglea BioTherapeutics received 47 more outperform votes than Spero Therapeutics when rated by MarketBeat users. However, 69.93% of users gave Spero Therapeutics an outperform vote while only 54.16% of users gave Aeglea BioTherapeutics an outperform vote. CompanyUnderperformOutperformAeglea BioTherapeuticsOutperform Votes25454.16% Underperform Votes21545.84% Spero TherapeuticsOutperform Votes20769.93% Underperform Votes8930.07% SummarySpero Therapeutics beats Aeglea BioTherapeutics on 14 of the 17 factors compared between the two stocks. Ad Investors AlleyStrange: Why is Amazon suddenly yielding 39.70%?Something big is happening with Amazon stock… While most investors collect ZERO dividends from Amazon… A small group just discovered a "backdoor" way to collect yields up to 39.70%!Click here to see this breakthrough before everyone else → Get Spero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRO vs. The Competition Export to ExcelMetricSpero TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$63.70M$6.38B$5.07B$8.66BDividend YieldN/A8.08%5.10%4.06%P/E Ratio16.8610.51100.6017.27Price / Sales0.61244.531,195.1369.06Price / Cash2.2953.4941.0336.35Price / Book0.589.306.345.87Net Income$22.81M$154.14M$119.64M$225.66M7 Day Performance-10.61%-9.47%-5.13%-1.34%1 Month Performance-8.17%-7.30%-2.72%1.15%1 Year Performance-0.84%28.21%31.10%24.02% Spero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPROSpero Therapeutics4.664 of 5 stars$1.18-5.6%$5.00+323.7%+1.7%$63.70M$103.78M16.8646Analyst ForecastShort Interest ↑News CoverageAGLEAeglea BioTherapeuticsN/AN/AN/AN/A$48.64M$2.33M-0.1669Analyst ForecastTTPHTetraphase PharmaceuticalsN/A$2.20flatN/A+0.0%$15.98M$7.38M-0.12119ATYRAtyr PHARMA2.996 of 5 stars$3.19-9.4%N/AN/A$267.77M$350,000.00-3.3956Short Interest ↑News CoverageBMEABiomea Fusion3.7157 of 5 stars$7.11+0.3%N/A-30.0%$257.67MN/A-1.7750LXEOLexeo Therapeutics2.4652 of 5 stars$7.78+1.8%N/A-40.0%$257.22M$650,000.00-0.5358Analyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeADCTADC Therapeutics2.8172 of 5 stars$2.65-6.0%N/A+275.8%$256.23M$69.56M-1.11310Short Interest ↓TCRXTScan Therapeutics2.4915 of 5 stars$4.82-8.2%N/A-7.2%$255.32M$21.05M-4.55100Earnings ReportAnalyst ForecastAnalyst RevisionNews CoveragePYXSPyxis Oncology0.95 of 5 stars$4.28flatN/A+185.0%$254.32MN/A-4.1660Short Interest ↑Analyst RevisionNews CoverageLFCRLifecore Biomedical2.7141 of 5 stars$6.68-5.8%N/A-13.9%$246.02M$128.26M83.50690ACRVAcrivon Therapeutics2.9924 of 5 stars$7.92-0.1%N/A+56.8%$245.28MN/A-2.8658Analyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies Aeglea BioTherapeutics Alternatives Tetraphase Pharmaceuticals Alternatives Atyr PHARMA Alternatives Biomea Fusion Alternatives Lexeo Therapeutics Alternatives ADC Therapeutics Alternatives TScan Therapeutics Alternatives Pyxis Oncology Alternatives Lifecore Biomedical Alternatives Acrivon Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SPRO) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
